Early detection and successful management of oral pemphigus vulgaris: A case report

Journal of Periodontology

Volumn 76, Issue 1, 2005, Pages 154-160

  Endo, Hiroyasu ^a   Rees, Terry D ^b   Matsue, Miyoko ^a   Kuyama, Kayo ^a   Nakadai, Mami ^a   Yamamoto, Hirotsugu ^a  

^a NIHON UNIVERSITY   (Japan)

^b BAYLOR COLLEGE OF DENTISTRY   (United States)

Author keywords

Gingival diseases therapy; Glucocorticoids therapeutic use; Outcome assessment; Pemphigus vulgaris diagnosis; Pemphigus vulgaris drug therapy

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; DESMOGLEIN 1; DESMOGLEIN 3; STEROID; TRIAMCINOLONE ACETONIDE;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CASE REPORT; CLINICAL FEATURE; CLINICAL STUDY; DIAGNOSTIC VALUE; DISEASE DURATION; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GINGIVA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; JAPAN; LONG TERM CARE; MEDICAL RESEARCH; MOUTH DISEASE; PEMPHIGUS VULGARIS; REMISSION; SURGICAL TECHNIQUE; TOOTH BRUSHING; TREATMENT OUTCOME; VALIDATION PROCESS; WOUND HEALING;

ADRENAL CORTEX HORMONES; CADHERINS; CYTOSKELETAL PROTEINS; DESMOGLEIN 1; DESMOGLEIN 3; DESMOGLEINS; DESMOPLAKINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GINGIVAL DISEASES; HUMANS; MIDDLE AGED; PEMPHIGUS;

EID: 15944371285     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2005.76.1.154     Document Type: Article

References (47)

1. Rees TD, Wright JM, Ammons WF Jr. Lesions in the oral mucous membranes and periodontium. In: Wilson TG Jr, Kornman KS, eds. Fundamentals of Periodontics, 2nd ed. Chicago: Quintessence Publishing Co. Inc; 2003:477-509.
2. Scully C, Challacombe SJ. Pemphigus vulgaris: Update on etiopathogenesis, oral manifestations, and management. Crit Rev Oral Biol Med 2002;13:397-408.
3. Korman N. Pemphigus. J Am Acad Dermatol 1988;18: 1219-1238.
4. Williams DM. Vesiculobullous mucocutaneous disease: Pemphigus vulgaris. J Oral Pathol Med 1989;18:544-553.
5. Scully C, Paes De Almeida O, Porter SR, Gilkes JJ. Pemphigus vulgaris: The manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol 1999;140:84-89.
6. Sirois DA, Fatahzadeh M, Roth R, Ettlin D. Diagnostic patterns and delays in pemphigus vulgaris: Experience with 99 patients. Arch Dermatol 2000;136:1569-1570.
7. Lamey PJ, Rees TD, Binnie WH, Wright JM, Rankin KV, Simpson NB. Oral presentation of pemphigus vulgaris and its response to systemic steroid therapy. Oral Surg Oral Med Oral Pathol 1992;74:54-57.
8. Davenport S, Chen SY, Miller AS. Pemphigus vulgaris: Clinicopathologic review of 33 cases in the oral cavity. Int J Periodontics Restorative Dent 2001;21:85-90.
9. Zegarelli DJ, Zegarelli EV. Intraoral pemphigus vulgaris. Oral Surg Oral Med Oral Pathol 1977;44:384-393.
10. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000;42:422-427.
11. Mashkilleyson N, Mashkilleyson AL. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm Venereol 1988;68:413-421.
12. Robinson JC, Lozada-Nur F, Frieden I. Oral pemphigus vulgaris: A review of the literature and a report on the management of 12 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;84:349-355.
13. Rees TD. Adjunctive therapy. Proceedings of the World Workshop in Clinical Periodontics. Chicago: The American Academy of Periodontology; 1989;X-1/X-39.
14. Kalish RS. Pemphigus vulgaris: The other half of the story. J Clin Invest 2000;106:1433-1435.
15. Yih WY, Maier T, Kratochvil FJ, Zieper MB. Analysis of desquamative gingivitis using direct immunofluorescence in conjunction with histology. J Periodontol 1998;69;678-685.
16. Rinaggio J, Neiders ME, Aguirre A, Kumar V. Using immunofluorescence in the diagnosis of chronic ulcerative lesions of the oral mucosa. Compendium Contin Educ Dent 1999;20:943-944.
17. Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999;103:461-468.
18. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992;90:919-926.
19. Amagai M, Komai A, Hashimoto T, et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999;140:351-357.
20. Lenz P, Amagai M, Volc-Platzer B, Stingl G, Kirnbauer R. Desmoglein 3-ELISA: A pemphigus vulgaris-specific diagnostic tool. Arch Dermatol 1999;135:143-148.
21. Harman KE, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The use of two substrates to improve the sensitivity of indirect immunofluorescence in the diagnosis of pemphigus. Br J Dermatol 2000;142:1135-1139.
22. Harman KE, Gratian MJ, Seed PT, Bhogal BS, Challacombe SJ, Black MM. Diagnosis of pemphigus by ELISA: A critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3. Clin Exp Dermatol 2000;25:236-240.
23. Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159:2010-2017.
24. Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999;40:167-170.
25. Shirakata Y, Amagai M, Hanakawa Y, Nishikawa T, Hashimoto K. Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1. J Invest Dermatol 1998;110:76-78.
26. Sams WM Jr, Jordon RE. Correlation of pemphigoid and pemphigus antibody titres with activity of disease. Br J Dermatol 1971;84:7-13.
27. O'Loughlin S, Goldman GC, Provost TT. Fate of pemphigus antibody following successful therapy. Preliminary evaluation of pemphigus antibody determinations to regulate therapy. Arch Dermatol 1978;114:1769-1772.
28. Beutner EH, Chorzelski TP, Jablonska S. Immunofluorescence tests. Clinical significance of sera and skin in bullous diseases. Int J Dermatol 1985;24:405-421.
29. Judd KP, Mescon H. Comparison of different epithelial substrates useful for indirect immunofluorescence testing of sera from patients with active pemphigus. J Invest Dermatol 1979;72:314-316.
30. Creswell SN, Black MM, Bhogal B, Skeete MV. Correlation of circulating intercellular antibody titres in pemphigus with disease activity. Clin Exp Dermatol 1981;6:477-483.
31. Acosta E, Gilkes JJ, Ivanyi L. Relationship between the serum autoantibody titers and the clinical activity of pemphigus vulgaris. Oral Surg Oral Med Oral Pathol 1985; 60:611-614.
32. Nisengard RJ. Periodontal implications: Mucocutaneous disorders. Ann Periodontol 1996;1:401-438.
33. McMillan R, Longmire R, Yelenosky R. The effect of corticosteroids on human IgG synthesis. J Immunol 1976; 116:1592-1595.
34. Ahmed AR, Moy R. Death in pemphigus. J Am Acad Dermatol 1982;7:221-228.
35. Meynadier J, Guilhou JJ, Peyron JL. Percutaneous absorption of triamcinolone 16 alpha, 17 alpha cyclopentylenedioxy-21 -acetate. Dermatologica 1981;162:336-341.
36. Hartmann F, Lahmann JJ. Effect of the external use of triamcinolone acetonide under foil occlussive dressings on the plasma cortisol level and on the diurnal rhythm of plasma cortisol. Hautarzt 1977;28:198-202.
37. Tamizi M, Moayedi M. Treatment of gingival lichen planus with a free gingival graft: A case report. Quintessence Int 1992;23:249-251.
38. Hovick CJ, Kalkwarf KL. Treatment of localized oral erosive lichen planus lesions with free soft tissue grafts. Periodontal Case Rep 1987;9:21-24.
39. Lorenzana ER, Rees TD, Hallmon WW. Esthetic management of multiple recession defects in a patient with cicatricial pemphigoid. J Periodontol 2001;72:230-237
40. Brain JH, Paul BF, Assad DA. Periodontal plastic surgery in a dystrophic epidermolysis bullosa patient: Review and case report. J Periodontol 1999;70:1392-1396.
41. Ratnam KV, Pang BK. Pemphigus in remission: Value of negative direct immunofluorescence in management. J Am Acad Dermatol 1994;30:547-550.
42. Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 2001; 144:775-780.
43. Bhol K, Mohimen A, Ahmed AR. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 1994;189:85-89.
44. Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: A model for autoimmunity. Proc Natl Acad Sci (USA) 1995;92:5239-5243.
45. Kricheli D, David M, Frusic-Zlotkin M, et al. The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first-degree relatives. Br J Dermatol 2000;143: 337-342.
46. Nguyen VT, Ndoye A, Grando SA. Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem 2000;275:29466-29476.
47. Nguyen VT, Ndoye A, Shultz LD, Pittelkow MR, Grando SA. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. J Clin Invest 2000;106:1467-1479.